Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nurix Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: http://www.nurix-inc.com
Year Founded: 2012
Status: Public
Industry Sector: HealthTechnology
CEO: Arthur T. Sands, MD, PhD
Number Of Employees: 286
Enterprise Value: $902,749,081
PE Ratio: -4.2
Exchange/Ticker 1: NASDAQ:NRIX
Exchange/Ticker 2: N/A
Latest Market Cap: $922,024,576
BioCentury | Jan 25, 2025
Management Tracks
Sara Brenner moves from CDHR to acting FDA commissioner
Plus: Northcott to lead commercial at Nurix, Bach joins Limani Partners and updates from the National MS Society, Octopus and Neurocrine
BioCentury | Oct 22, 2024
Deals
Pfizer deepens degrader footprint, Novartis taps China’s Baiyu, and more
Deals report: Pfizer-Triana to discover molecular glues; Novartis taps Baiyu for cancer small molecule; plus Ocean-Molecure, Takeda-Wave and more
BioCentury | Jul 18, 2024
Management Tracks
Rosenberg named CFO of BeiGene
Plus: CEO Barbier, SVP Burns leave Cassava, and updates from Rezo and Haya
BioCentury | Jun 19, 2024
Product Development
Clinical Report: Zentalis hold resurfaces WEE1 safety concerns
Plus data from BioNTech, MediLink, Nurix, Aerovate and more
BioCentury | May 29, 2024
Management Tracks
Nurix promotes O’Connor to CMO, Phiasivongsa to CTO
Plus: NodThera names Daniel Swisher CEO, and updates from Cogent, Sapreme and Biocom
BioCentury | May 22, 2024
Management Tracks
Eden Wells to lead insights and decision science at Novartis
Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos
BioCentury | Apr 12, 2024
Finance
Public equity report: Acrivon refreshes balance sheet with $130M PIPE
Plus Eliem, Century raise private placements as they make acquisitions; Nurix’s AACR readout precedes follow-on; Skye uplists
BioCentury | Apr 10, 2024
Product Development
AACR roundup: BioNTech shows personalized neoantigen vaccines are durable
Plus: Readouts from Geneos, BMS and Nurix
BioCentury | Mar 30, 2024
Discovery & Translation
Combining ADCs with protein degraders could widen the therapeutic windows of both
Degrader-antibody conjugates double up on selectivity, but ‘DACs’ present optimization challenge
BioCentury | Sep 8, 2023
Deals
Sept. 7 Quick Takes: Seagen, Nurix in deal to create degrader-antibody conjugates
Plus: U.K. rejoins Horizon Europe and more from Mariana, Corteria, Noetik, CymaBay, J&J, Alnylam and BlueWhale
Items per page:
1 - 10 of 47